We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.41B
AUM Growth
+$274M
Cap. Flow
+$112M
Cap. Flow %
4.66%
Top 10 Hldgs %
24.57%
Holding
158
New
13
Increased
40
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$31.6M
2
TECX
Tectonic Therapeutic
TECX
+$27.9M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$22.5M
4
PANW icon
Palo Alto Networks
PANW
+$20.8M
5
SAGE
Sage Therapeutics
SAGE
+$18.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$52M
2
CAFD
8point3 Energy Partners LP
CAFD
+$18.9M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$18M
4
TWLO icon
Twilio
TWLO
+$12.5M
5
SNA icon
Snap-on
SNA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 42.26%
2 Technology 16.99%
3 Consumer Discretionary 12.15%
4 Industrials 8.07%
5 Utilities 2.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.59B
$8.44M 0.35%
228,000
– –
ARGX icon
77
argenx
ARGX
$54.6B
$8.29M 0.34%
100,000
– –
EXR icon
78
Extra Space Storage
EXR
$31.3B
$7.99M 0.33%
80,000
-3,000
-4% -$279K
REGN icon
79
Regeneron Pharmaceuticals
REGN
$77.4B
$7.93M 0.33%
23,000
– –
EXAS
80
DELISTED
Exact Sciences
EXAS
$7.83M 0.33%
131,000
– –
SUPN icon
81
Supernus Pharmaceuticals
SUPN
$2.65B
$7.78M 0.32%
130,000
– –
RCKT icon
82
Rocket Pharmaceuticals
RCKT
$351M
$7.75M 0.32%
394,585
– –
FENC icon
83
Fennec Pharmaceuticals
FENC
$344M
$7.74M 0.32%
741,175
– –
INCY icon
84
Incyte
INCY
$24.9B
$7.71M 0.32%
115,000
+84,000
+271% +$5.74M
KALV
85
DELISTED
KalVista Pharmaceuticals
KALV
$7.31M 0.3%
900,000
– –
BMRN icon
86
BioMarin Pharmaceuticals
BMRN
$11.7B
$7.07M 0.29%
75,000
– –
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.72M 0.28%
87,400
– –
CERN
88
DELISTED
Cerner Corp
CERN
$6.47M 0.27%
108,200
– –
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$27.4B
$6.11M 0.25%
62,000
– –
RGEN icon
90
Repligen
RGEN
$7.03B
$5.17M 0.21%
110,000
– –
KNSA icon
91
Kiniksa Pharmaceuticals
KNSA
$6.1B
$5.14M 0.21%
+296,400
New +$5.36M
ANAB icon
92
AnaptysBio
ANAB
$1.63B
$5.12M 0.21%
+72,000
New +$6.04M
VBIV
93
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$5.09M 0.21%
61,667
– –
ECYT
94
DELISTED
Endocyte, Inc. Common Stock
ECYT
$4.83M 0.2%
350,000
– –
VIRX
95
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.8M 0.2%
64,727
– –
RARX
96
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.86M 0.16%
388,000
– –
LKFT
97
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$3.69M 0.15%
40,000
– –
IRWD icon
98
Ironwood Pharmaceuticals
IRWD
$614M
$3.67M 0.15%
229,248
– –
IOVA icon
99
Iovance Biotherapeutics
IOVA
$2.09B
$3.58M 0.15%
+280,000
New +$4.09M
EIDX
100
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$3.29M 0.14%
+162,000
New +$3.4M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Eventide Asset Management held 158 positions worth $2.41B, up 13% from $2.14B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management deployed $112M of net new capital in Q2 2018, opening 13 new positions and adding to 40 existing holdings. Its largest new stake was Dianthus Therapeutics: 139,881 shares worth $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Snap-on, an estimated $10.6M trimmed.

  • Eventide Asset Management's largest Q2 2018 buy was Dianthus Therapeutics: 139,881 shares worth $29.5M.
  • Eventide Asset Management added most to Myovant Sciences Ltd. in Q2 2018, an estimated $22.5M increase.
  • Eventide Asset Management's biggest Q2 2018 reduction was Snap-on, cutting an estimated $10.6M.
  • Eventide Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $2.41B portfolio in Q2 2018.
  • Eventide Asset Management opened 13 new positions and closed 14 in Q2 2018.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $2.41B.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.